Mouse experiments show that differences in bacterial composition and metabolism in the gut and bile modulate intestinal Farnesoid X receptor (FXR) signaling, and that elevated concentrations of FXR excitatory factors increase the incidence of metabolic diseases (Sun et al., 2021). Here, NR1H4 is linked to metabolic disease.